<code id='DD660B4386'></code><style id='DD660B4386'></style>
    • <acronym id='DD660B4386'></acronym>
      <center id='DD660B4386'><center id='DD660B4386'><tfoot id='DD660B4386'></tfoot></center><abbr id='DD660B4386'><dir id='DD660B4386'><tfoot id='DD660B4386'></tfoot><noframes id='DD660B4386'>

    • <optgroup id='DD660B4386'><strike id='DD660B4386'><sup id='DD660B4386'></sup></strike><code id='DD660B4386'></code></optgroup>
        1. <b id='DD660B4386'><label id='DD660B4386'><select id='DD660B4386'><dt id='DD660B4386'><span id='DD660B4386'></span></dt></select></label></b><u id='DD660B4386'></u>
          <i id='DD660B4386'><strike id='DD660B4386'><tt id='DD660B4386'><pre id='DD660B4386'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:1982

          Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from wastes of time when it comes to AI in biotech.

          advertisement

          For more on what we cover, here’s the latest on AI in drug development; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          Wikipedia

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Roivant's CEO is a star, but biotech's black hole persists
          Roivant's CEO is a star, but biotech's black hole persists

          MollyFerguson/STATRoivantSciences’MattGlinemightbethisyear’sbestbiopharmaCEO,andotherthoughtsaboutMo

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

          Advancesingenetherapycouldeventually"cure"manyformsofcongenitaldeafness.Thechangeshavemanydeafpeople